keyword
MENU ▼
Read by QxMD icon Read
search

immunogenicity vaccine

keyword
https://www.readbyqxmd.com/read/29678552/the-immunogenicity-of-recombinant-vaccines-based-on-modified-vaccinia-ankara-mva-viruses-expressing-african-horse-sickness-virus-vp2-antigens-depends-on-the-levels-of-expressed-vp2-protein-delivered-to-the-host
#1
Eva Calvo-Pinilla, Simon Gubbins, Peter Mertens, Javier Ortego, Javier Castillo-Olivares
African horse sickness (AHS) is a lethal equine disease transmitted by Culicoides biting midges and caused by African horse sickness virus (AHSV). AHS is endemic to sub-Saharan Africa, but devastating outbreaks have been recorded periodically outside this region. The perceived risk of an AHS outbreak occurring in Europe has increased following the frequent epidemics caused in ruminants by bluetongue virus, closely related to AHSV. Attenuated vaccines for AHS are considered unsuitable for use in non-endemic countries due bio-safety concerns...
April 17, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29678458/immunization-of-balb-c-mice-with-a-combination-of-four-recombinant-brucella-abortus-proteins-aspc-dps-inpb-and-ndk-confers-a-marked-protection-against-a-virulent-strain-of-brucella-abortus
#2
Huynh Tan Hop, Lauren Togonon Arayan, Tran Xuan Ngoc Huy, Alisha Wehdnesday Bernardo Reyes, WonGi Min, Hu Jang Lee, Soo Jong Park, Hong Hee Chang, Suk Kim
In this study, we assessed the protective efficacy of single subunit vaccines, encoded by the B. abortus 544 genes aspC, dps, yaeC and inpB, against B. abortus infection in mice. First, immunization with these antigens, with the exception of the YaeC protein, was found to elicit both humoral and cellular immune responses with IgG2a being dominant over IgG1. In addition, a massive production of IFN-γ but lower degree of IL-10 was observed, suggesting that all three antigens were able to induce predominantly cell-mediated immunity in response to B...
April 17, 2018: Vaccine
https://www.readbyqxmd.com/read/29677646/adjuvant-strategies-to-improve-vaccination-of-the-elderly-population
#3
REVIEW
Birgit Weinberger
Immunosenescence contributes to increased incidence and severity of many infections in old age and is responsible for impaired immunogenicity and efficacy of vaccines. Adjuvants are one strategy to enhance immunogenicity of vaccines. The oil-in-water emulsions MF59TM and AS03, as well as a virosomal vaccine have been licensed in seasonal or pandemic influenza vaccines and are/were used successfully in the elderly. AS01, a liposome-based adjuvant comprising two immunostimulants has recently been approved in a recombinant protein vaccine for older adults, which showed very high efficacy against herpes zoster in clinical trials...
April 17, 2018: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29675803/drosophila-s2-cell-culture-in-a-wave-bioreactor-potential-for-scaling-up-the-production-of-the-recombinant-rabies-virus-glycoprotein
#4
Monize Caiado Decarli, Diogo Peres Dos Santos, Renato Mancini Astray, Daniella Cristina Ventini-Monteiro, Soraia Attie Calil Jorge, Daniela Matilde Correia, Juliana de Sá da Silva, Mayra Pereira Rocca, Hélio Langoni, Benedito Donizete Menozzi, Carlos Augusto Pereira, Claudio Alberto Torres Suazo
The transmembrane rabies virus glycoprotein (RVGP) is the main antigen of vaccine formulations used around the world to prevent rabies, the most lethal preventable infectious disease known. The objective of this work was to evaluate the potential of a bioreactor using wave-induced agitation in the initial steps of scaling up the rRVGP production process by a Drosophila melanogaster S2 cell line to produce rRVGP in sufficient quantities for immunization and characterization studies. Taking advantage of some remarkable features recognized in Drosophila S2 cells for scaling the culture process, a robust recombinant lineage (S2MtRVGPH-His) engineered by our group for the expression of rRVGP using a copper-inducible promoter was used in the bioreactor cultures...
April 19, 2018: Applied Microbiology and Biotechnology
https://www.readbyqxmd.com/read/29675401/analysis-of-the-antigenic-and-prophylactic-properties-of-the-leishmania-translation-initiation-factors-eif2-and-eif2b-in-natural-and-experimental-leishmaniasis
#5
Esther Garde, Laura Ramírez, Laura Corvo, José C Solana, M Elena Martín, Víctor M González, Carlos Gómez-Nieto, Aldina Barral, Manoel Barral-Netto, José M Requena, Salvador Iborra, Manuel Soto
Different members of intracellular protein families are recognized by the immune system of the vertebrate host infected by parasites of the genus Leishmania . Here, we have analyzed the antigenic and immunogenic properties of the Leishmania eIF2 and eIF2B translation initiation factors. An in silico search in Leishmania infantum sequence databases allowed the identification of the genes encoding the α, β, and γ subunits and the α, β, and δ subunits of the putative Leishmania orthologs of the eukaryotic initiation factors F2 (LieIF2) or F2B (LieIF2B), respectively...
2018: Frontiers in Cellular and Infection Microbiology
https://www.readbyqxmd.com/read/29675174/a-modular-synthetic-route-to-size-defined-immunogenic-haemophilus-influenzae-b-antigens-is-key-to-the-identification-of-an-octasaccharide-lead-vaccine-candidate
#6
J Y Baek, A Geissner, D C K Rathwell, D Meierhofer, C L Pereira, P H Seeberger
The first glycoconjugate vaccine using isolated glycans was licensed to protect children from Haemophilus influenzae serotype b (Hib) infections. Subsequently, the first semisynthetic glycoconjugate vaccine using a mixture of antigens derived by polymerization targeted the same pathogen. Still, a detailed understanding concerning the correlation between oligosaccharide chain length and the immune response towards the polyribosyl-ribitol-phosphate (PRP) capsular polysaccharide that surrounds Hib remains elusive...
February 7, 2018: Chemical Science
https://www.readbyqxmd.com/read/29674167/neuraminidase-as-an-influenza-vaccine-antigen-a-low-hanging-fruit-ready-for-picking-to-improve-vaccine-effectiveness
#7
REVIEW
Maryna C Eichelberger, David M Morens, Jeffery K Taubenberger
Neuraminidase (NA) plays an essential role in influenza virus replication, facilitating multicycle infection predominantly by releasing virions from infected cells. NA-inhibiting antibodies provide resistance to disease and NA-specific antibodies contribute to vaccine efficacy. The primary reason NA vaccine content and immunogenicity was not routinely measured in the past, was the lack of suitable assays to quantify NA and NA-specific antibodies. These are now available and with recent appreciation of its contribution to immunity, NA content of seasonal and pandemic vaccines is being considered...
April 16, 2018: Current Opinion in Immunology
https://www.readbyqxmd.com/read/29673942/allergic-patients-with-and-without-allergen-specific-immunotherapy-mount-protective-immune-responses-to-tick-borne-encephalitis-vaccination-in-absence-of-enhanced-side-effects-or-propagation-of-their-th2-bias
#8
Erika Garner-Spitzer, Claudia Seidl-Friedrich, Ines Zwazl, Michael Hofer, Tamar Kinaciyan, Reinhart Jarisch, Karin Stiasny, Gerhard J Zlabinger, Michael Kundi, Ursula Wiedermann
BACKGROUND: Allergic diseases are caused by Th2-driven immune responses and their treatment with specific immunotherapy (SIT) leads to immunomodulation via IL10, TGF-ß and Th1/Tr1 shift. This phase IV, open-label clinical trial investigated whether allergies and SIT treatment influenced immune responses to routine vaccination. METHODS: We studied three groups: 49 allergic patients (allergic group), 21 allergic patients receiving maintenance doses of SIT (SIT group), and 49 non-allergic controls...
April 16, 2018: Vaccine
https://www.readbyqxmd.com/read/29673941/use-of-hepatitis-a-vaccine-for-post-exposure-prophylaxis-in-individuals-over-40-years-of-age-a-systematic-review-of-published-studies-and-recommendations-for-vaccine-use
#9
REVIEW
Ruth Link-Gelles, Megan G Hofmeister, Noele P Nelson
INTRODUCTION: Hepatitis A can cause widespread outbreaks. Until 2018, postexposure prophylaxis (PEP) in the United States for individuals >40 years consisted of immune globulin (IG) administered as soon as possible after exposure, ideally within 14 days whereas those aged ≤40 should receive hepatitis A (HepA) vaccine. However, state health departments reporting difficulty quickly accessing and administering IG, costs of higher IG doses and importance of long-term HAV protection prompted CDC to review immunogenicity data for use of HepA vaccine for PEP in older adults...
April 16, 2018: Vaccine
https://www.readbyqxmd.com/read/29673645/intranasal-delivery-of-adjuvant-free-peptide-nanofibers-elicits-resident-cd8-t-cell-responses
#10
Youhui Si, Yi Wen, Sean H Kelly, Anita S Chong, Joel H Collier
Influenza vaccines that can be administered intranasally or by other needle-free delivery routes have potential advantages over injected formulations in terms of patient compliance, cost, and ease of global distribution. Supramolecular peptide nanofibers have been investigated previously as platforms for vaccines and immunotherapies and have been shown to raise immune responses in the absence of exogenous adjuvants and without measurable inflammation. However, at present it has not been tested whether the immunogenicity of these materials extends to the intranasal route...
April 16, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29673285/tlr-agonist-combinations-that-stimulate-th-type-i-polarizing-responses-from-human-neonates
#11
Naveen Surendran, Andrea Simmons, Michael E Pichichero
Each year millions of neonates die due to vaccine preventable infectious diseases. Our study seeks to develop novel neonatal vaccines and improve immunogenicity of early childhood vaccines by incorporating TLR agonist-adjuvant combinations that overcome the inherent neonatal Th2 bias and stimulate Th1 polarizing response from neonatal APCs. We systematically stimulated cord blood mononuclear cells with single and multiple combinations of TLR agonists and measured levels of IL-12p70, IFN-γ, IFN-α, IL-10, IL-13, TNF-α, IL-6 and IL-1β from cell culture supernatants...
January 1, 2018: Innate Immunity
https://www.readbyqxmd.com/read/29671067/vaccinations-in-pediatric-kidney-transplant-recipients
#12
REVIEW
Thomas G Fox, Corina Nailescu
Pediatric kidney transplant (KT) candidates should be fully immunized according to routine childhood schedules using age-appropriate guidelines. Unfortunately, vaccination rates in KT candidates remain suboptimal. With the exception of influenza vaccine, vaccination after transplantation should be delayed 3-6 months to maximize immunogenicity. While most vaccinations in the KT recipient are administered by primary care physicians, there are specific schedule alterations in the cases of influenza, hepatitis B, pneumococcal, and meningococcal vaccinations; consequently, these vaccines are usually administered by transplant physicians...
April 18, 2018: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/29670634/robust-humoral-and-cellular-immune-responses-to-pertussis-in-adults-after-a-first-acellular-booster-vaccination
#13
Saskia van der Lee, Debbie M van Rooijen, Mary-Lène de Zeeuw-Brouwer, Marjan J M Bogaard, Pieter G M van Gageldonk, Axel Bonacic Marinovic, Elisabeth A M Sanders, Guy A M Berbers, Anne-Marie Buisman
Introduction: To reduce the pertussis disease burden, nowadays several countries recommend acellular pertussis (aP) booster vaccinations for adults. We aimed to evaluate the immunogenicity of a first adult aP booster vaccination at childbearing age. Methods: In 2014, healthy adults aged 25-29 years ( n  = 105), vaccinated during infancy with four doses of whole-cell pertussis (wP) vaccine, received a Tdap (tetanus, diphtheria, and aP) booster vaccination. Blood samples were collected longitudinally pre-booster, 2 and 4 weeks, and 1 year and 2 years post-booster...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29670587/influenza-viral-vectors-expressing-two-kinds-of-ha-proteins-as-bivalent-vaccine-against-highly-pathogenic-avian-influenza-viruses-of-clade-2-3-4-4-h5-and-h7n9
#14
Jinping Li, Guangyu Hou, Yan Wang, Suchun Wang, Cheng Peng, Xiaohui Yu, Wenming Jiang
The H5 and H7N9 subtypes of highly pathogenic avian influenza viruses (HPAIVs) in China pose a serious challenge to public health and the poultry industry. In this study, a replication competent recombinant influenza A virus of the Í5N1 subtype expressing the H7 HA1 protein from a tri-cistronic NS segment was constructed. A heterologous dimerization domain was used to combine with the truncated NS1 protein of 73 amino acids to increase protein stability. H7 HA1, nuclear export protein coding region, and the truncated NS1 were fused in-frame into a single open reading frame via 2A self-cleaving peptides...
2018: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29669838/effects-of-adjuvants-on-hiv-1-envelope-glycoprotein-sosip-trimers-in-vitro
#15
Gabriel Ozorowski, Albert Cupo, Michael Golabek, Michelle LoPiccolo, Thomas A Ketas, Matt Cavallary, Christopher A Cottrell, P J Klasse, Andrew B Ward, John P Moore
Native-like, soluble, recombinant SOSIP trimers of various designs and based on several env genes of human immunodeficiency virus type 1 (HIV-1) are being tested as immunogens in different animal models. These experiments almost always involve co-formulating the trimers with an adjuvant to boost the magnitude of the immune responses. One factor relevant to the choice of an adjuvant is that it should not physically damage the immunogen or impede its ability to present relevant epitopes. As examples, an adjuvant formulation that includes harsh detergents could disrupt the structural integrity of a trimer, and any charged compounds in the formulation could bind to counter-charged regions of the trimer and physically occlude nearby epitopes...
April 18, 2018: Journal of Virology
https://www.readbyqxmd.com/read/29669664/evaluating-children-with-suspected-allergic-reactions-to-vaccines-for-infectious-diseases
#16
Fabrizio Franceschini, Paolo Bottau, Silvia Caimmi, Fabio Cardinale, Giuseppe Crisafulli, Lucia Liotti, Guido Pellegrini, Diego Peroni, Francesca Saretta, Carla Mastrorilli, Carlo Caffarelli
BACKGROUND: Vaccines often contain potentially allergenic material in addition to pathogen-specific immunogens that may induce allergic reactions. Parents and physicians often suspect that adverse reactions to vaccines are allergic in etiology. The concern that some of the substances contained in vaccines may trigger an anaphylactic reaction may lead to a low vaccination adherence with emergence of infectious disease epidemics. OBJECTIVE: To provide practical suggestions for managing children suspected to have an allergic reaction to a vaccine...
May 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29669531/assessment-of-an-optimized-manufacturing-process-for-inactivated-quadrivalent-influenza-vaccine-a-phase-iii-randomized-double-blind-safety-and-immunogenicity-study-in-children-and-adults
#17
Carine Claeys, Mamadou Drame, José García-Sicilia, Khalequ Zaman, Alfonso Carmona, Phu My Tran, Mariano Miranda, Federico Martinón-Torres, Franck Thollot, Michael Horn, Tino F Schwarz, Ulrich Behre, José M Merino, Iwona Sadowska-Krawczenko, Henryk Szymański, Peter Schu, Elisabeth Neumeier, Ping Li, Varsha K Jain, Bruce L Innis
BACKGROUND: GSK has modified the licensed monovalent bulk manufacturing process for its split-virion inactivated quadrivalent influenza vaccine (IIV4) to harmonize the process among different strains, resulting in an increased number of finished vaccine doses, while compensating for the change from inactivated trivalent influenza vaccine (IIV3) to IIV4. To confirm the manufacturing changes do not alter the profile of the vaccine, a clinical trial was conducted to compare IIV4 made by the currently licensed process with a vaccine made by the new (investigational) process (IIV4-I)...
April 18, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29669026/first-in-human-randomized-controlled-trial-of-mosaic-hiv-1-immunogens-delivered-via-a-modified-vaccinia-ankara-vector
#18
Lindsey R Baden, Stephen R Walsh, Michael S Seaman, Yehuda Z Cohen, Jennifer A Johnson, J Humberto Licona, Rachel D Filter, Jane A Kleinjan, Jon A Gothing, Julia Jennings, Lauren Peter, Joseph Nkolola, Peter Abbink, Erica N Borducchi, Marinela Kirilova, Kathryn E Stephenson, Poonam Pegu, Michael A Eller, Hung V Trinh, Mangala Rao, Julie A Ake, Michal Sarnecki, Steven Nijs, Katleen Callewaert, Hanneke Schuitemaker, Jenny Hendriks, Maria G Pau, Frank Tomaka, Bette T Korber, Galit Alter, Raphael Dolin, Patricia L Earl, Bernard Moss, Nelson L Michael, Merlin L Robb, Dan H Barouch
Background: Mosaic immunogens are bioinformatically engineered HIV-1 sequences designed to elicit clade independent coverage against globally circulating HIV-1 strains. Methods: This Phase 1 double-blind, randomized, placebo-controlled trial enrolled healthy HIV uninfected adults who received two doses of a modified vaccinia Ankara (MVA) vectored HIV-1 bivalent mosaic immunogen vaccine or placebo on days 0 and 84. Two groups were enrolled: those who were HIV-1 vaccine naïve (N=15) and those who had received an HIV-1 vaccine four to six years earlier (Ad26...
April 13, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29668023/common-queries-about-immunizations-in-preterm-infants
#19
Ansul Asad
Preterm infants are at an increased risk of morbidity and mortality from vaccine-preventable diseases. Despite this, delays in routine immunization of preterm infants are common. Available guidelines clearly state that they should be immunized according to chronological age, irrespective of gestational age and birth weight or current weight. In this article, we try to assuage parental and provider doubts by reviewing data about immunogenicity, safety, and responses to routine immunizations in preterm infants with and without comorbidities...
April 1, 2018: Pediatric Annals
https://www.readbyqxmd.com/read/29667004/the-development-of-hiv-vaccines-targeting-gp41-membrane-proximal-external-region-mper-challenges-and-prospects
#20
REVIEW
Huan Liu, Xiaojie Su, Lulu Si, Lu Lu, Shibo Jiang
A human immunodeficiency virus type-1 (HIV-1) vaccine which is able to effectively prevent infection would be the most powerful method of extinguishing pandemic of the acquired immunodeficiency syndrome (AIDS). Yet, achieving such vaccine remains great challenges. The membrane-proximal external region (MPER) is a highly conserved region of the envelope glycoprotein (Env) gp41 subunit near the viral envelope surface, and it plays a key role in membrane fusion. It is also the target of some reported broadly neutralizing antibodies (bNAbs)...
April 17, 2018: Protein & Cell
keyword
keyword
99930
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"